Summit Place Financial Advisors LLC Sells 67 Shares of Zoetis Inc. (NYSE:ZTS)

Summit Place Financial Advisors LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,389 shares of the company’s stock after selling 67 shares during the quarter. Zoetis accounts for approximately 1.6% of Summit Place Financial Advisors LLC’s investment portfolio, making the stock its 28th biggest holding. Summit Place Financial Advisors LLC’s holdings in Zoetis were worth $2,833,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB raised its position in shares of Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after purchasing an additional 20,001 shares during the period. Creative Planning grew its stake in shares of Zoetis by 8.6% in the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after acquiring an additional 7,170 shares in the last quarter. Howard Capital Management Group LLC grew its stake in shares of Zoetis by 0.8% in the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after acquiring an additional 883 shares in the last quarter. Cyndeo Wealth Partners LLC acquired a new position in shares of Zoetis in the third quarter valued at about $244,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Zoetis by 8.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock valued at $10,882,000 after acquiring an additional 4,107 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.7 %

Shares of NYSE ZTS opened at $156.43 on Wednesday. The company has a 50 day simple moving average of $167.70 and a 200 day simple moving average of $178.44. The firm has a market cap of $70.05 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, research analysts forecast that Zoetis Inc. will post 6.06 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $214.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.